title: [Clinicopathologic features of peripheral neuroblastic tumors].
abstract: OBJECTIVE
  To study the clinicopathologic characteristics of peripheral neuroblastic tumors and to evaluate the prognostic significance of these features.
  
  
  METHODS
  The clinical and pathologic findings were retrospectively reviewed in 121 cases of peripheral neuroblastic tumor. The clinical outcomes of patients were evaluated. The three-year event-free survival rate was analyzed, with respect to age of patients, Evan's staging, International Neuroblastoma Pathology Classification and mitosis-karyorrhexis index.
  
  
  RESULTS
  The median age at diagnosis was 2.7 years; and 96 cases (79.3%) occurred in patients younger than 5 years old. The number of cases in Evan's staging I, II, III, IV and IVs was 24, 39, 24, 29 and 5, respectively. There were 82 cases of neuroblastoma (NB) (including 2 cases of undifferentiated NB, 52 cases of poorly differentiated NB and 28 cases of differentiating NB), 9 cases of ganglioneuroblastoma, intermixed type (GNBi), 19 cases of ganglioneuroma, maturing type (GN) and 11 cases of ganglioneuroblastoma, nodular type (GNBn). Forty-nine cases were in the favorable histology subgroup and 72 cases in the unfavorable histology subgroup. The overall three-year event-free survival rate of the 121 cases was 73.0% ± 4.3%. The three-year event-free survival rates were associated with age (P = 0.002), Evan's staging (P = 0.000), histologic category (P = 0.000), mitosis-karyorrhexis index (P = 0.043), prognostic subgroup (P = 0.000).
  
  
  CONCLUSIONS
  Most of the peripheral neuroblastic tumors occur in the children younger than 5 years old. It is composed of NB, GNBi, GN and GNBn. The three-year event-free survival rate is approximately 70%. Significant prognostic parameters include age of patients, Evan's staging, International Neuroblastoma Pathology Classification and mitosis-karyorrhexis index.
authors.affiliation: Department of Pathology, Capital Medical University, Beijing, China.
authors.forename: Bao-feng
authors.initials: BF
authors.lastname: Yang
authors.forename: Li-bing
authors.initials: LB
authors.lastname: Fu
authors.forename: Le-jian
authors.initials: LJ
authors.lastname: He
mesh_terms: D000367:Age Factors; D034961:Antigens, Nuclear / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018305:Ganglioneuroblastoma / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D005729:Ganglioneuroma / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009367:Neoplasm Staging; D009419:Nerve Tissue Proteins / Q000378:metabolism; D064231:Nestin / Q000378:metabolism; D009447:Neuroblastoma / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D010524:Peripheral Nervous System Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D010751:Phosphopyruvate Hydratase / Q000378:metabolism; D012189:Retrospective Studies; D009418:S100 Proteins / Q000378:metabolism
chemical_list: D034961:Antigens, Nuclear; D009419:Nerve Tissue Proteins; D064231:Nestin; D009418:S100 Proteins; C506808:neuronal nuclear antigen NeuN, human; D010751:Phosphopyruvate Hydratase